TNF and rheumatoid arthritis: Over the past several decades, advances in the treatment and management of RA have occurred, including the introduction of inflammation-reducing medications such as anti-TNF- α agents beginning in the 1990 and 2000 s in North America, and the shift towards a treat-to-target approach in 2010, which targets remission or low disease activity [38, 39].